PPAR : a dagger in the heart of the metabolic syndrome
Open accessThe DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.
Abstract
Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both overexpression and activation of PPARδ result in increased mitochondrial biogenesis in the absence of an increase in PGC-1α mRNA in skeletal muscle in vivo (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The finding that overexpression of PPARδ in skeletal muscle of transgenic mice does not result in an increase in PGC-1α mRNA led to the conclusion that the increase in mitochondria is mediated directly by PPARδ (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to the finding in mouse and rat skeletal muscle that PPARδ overexpression or activation does not result in an increase in PGC-1α mRNA, a number of studies have shown that PPARδ induces an increase in PGC-1α gene transcription, with a rapid increase in PGC-1α mRNA, in myotubes (19, 50, 51).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The regulation of PGC-1α expression by PPARδ differs markedly between skeletal muscle in vivo and myotubes in culture.”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Research works printed but not linked: 1
- [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
Cited by
Items 701–738 of 738
Norepinephrine Spares Adipose Tissue in Ovine Fetuses Complicated with Placental Insufficiency
Luna Ramirez, R. I., & Luna Ramirez, R. I. (2019) · UA Campus Repository (The University of Arizona)
Kemmerer, M. (2016) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt)
SOSTANZE E METODI DOPANTI: USI, EFFETTI COLLATERALI E PROCEDIMENTI DI ANALISI
BOGGIATTO, C. (2015) · Electronic Theses and Dissertations Repository (University of Pisa)
PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma
Niu, D., Wei, D., Liu, Y., Yao, J. C., Shureiqi, I., & Zuo, X. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218385
Intestinal and skin homeostasis : targeting inflammation and cancer
El‐Jamal, N. (2012) · theses.fr (ABES) · doi:10.70675/19534eecz98c4z48b2z92f6z0eb4d568fe93
塩地英希, Shiochi, H., Shiochi, H., Shiochi, H., & 39981 (2016) · Institutional Repositories DataBase (IRDB)
Habarou, F. (2016) · theses.fr (ABES) · doi:10.70675/b26b7ae1zde58z4b98z9a12zf228c85c0a47
Song, W., Dong, Y., Wang, X., Xu, F., Jiang, B., Zhou, Y., & Li, Q. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153768
Hu, X., Li, H., Zhang, Q., (40767), Y. Z., Lv, Z., Zou, T., Tang, R., & Zhang, X. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.115102
A Systems Pharmacology Study on Lanifibranor for the Management of Non-Alcoholic Fatty Liver Disease
Sunkara, R., & Chimakurthy, J. (2026) · Current Trends in Biotechnology and Pharmacy · doi:10.5530/ctbp.2026.2s.14
PPARδ in neurological diseases: Mechanisms and therapeutic prospects
Liu, Y., Hu, Z., Luo, H., Li, M., Li, S., Xu, Y., Shi, C., & Tang, M. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107514
Öner-İyidoğan, Y., & Koçak, H. (2026) · Cells · doi:10.3390/cells15141262
“PPAR-α activation enhances fatty acid oxidation, whereas PPAR-γ regulates lipid storage and insulin sensitivity [9,11,17,58].”
InfluentialSP, M. T. M., Habib, M. R., Tokutake, Y., & Yonekura, S. (2026) · Animal Science Journal · doi:10.1111/asj.70221
The enabling power of chemical probes: examples from the nuclear hormone receptor field
Willson, T. M., & Merk, D. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260016
Suk, K. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118407
Ferroptosis Regulates Metabolic Inflammation–Driven Tumorigenesis in Obesity-Related Gastric Cancer
Tanabe, M., Uno, K., Tamahara, T., Asano, N., Koshiba, S., Kusano, K., Ogasawara, K., Kaise, Y., Saito, M., Koike, T., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101900
BindingDB Entry 50008260: Structure optimization of a new class of PPARγ antagonists.
BindingDB (2021) · UC San Diego · doi:10.7270/q20c5043
BindingDB Entry 50020727: Indanylacetic acids as PPAR-delta activator insulin sensitizers.
BindingDB (2009) · UC San Diego · doi:10.7270/q2gx4b8h
Efecte de l'activació de PPARβ/δ sobre l'oxidació d'àcids grassos i el procés inflamatori
Barroso, E. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Papel del receptor nuclear PPARgamma en la inflamación y la esteatosis hepática
Salvador, E. M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Immunomodulatory Pathways and Metabolism
Bhargava, P. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Metadata
- Authors
- Barish, G. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Barish, G. D.
- ORCID
- Barish, G. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 590-597
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1386117
- OpenAlex
- W1987601141
- Cited by
- 641
- References
- 100
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- March of Dimes Foundation
- Larry L. Hillblom Foundation
- National Institutes of Health (U19DK62434)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
- National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
- MeSH terms
- Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.